论文部分内容阅读
目的观察国产多西他赛注射液对一线治疗后失败的晚期乳腺癌患者的临床疗效及毒副反应,并对安全性进行评估。方法以国产多西他赛对44例既往治疗后进展的乳腺癌患者进行70mg/m~2静脉滴注,每3周1次,单药治疗。试验中不预防使用粒细胞集落刺激因子。用世界卫生组织(WHO)的疗效及抗肿瘤药急性及亚急性毒性反应分度标准评价疗效及毒性,用卡式评分评价身体状况变化。结果在41例可评价疗效的患者中,4例达到完全缓解,14例部分缓解,有效率达43．9%,临床获益率85．4%。不良反应主要表现为Ⅲ、Ⅳ度白细胞下降(42．9%)、脱发(7．1%)和消化道反应(4．8%)。未出现水钠潴留。结论使用多西他赛注射液治疗化疗后进展的晚期乳腺癌患者,疗效显著,耐受性良好,可作为该类患者的治疗选择。
Objective To observe the clinical efficacy and side effects of domestic injection of docetaxel on patients with advanced breast cancer who failed after the first-line treatment and evaluate the safety. Methods Domestic docetaxel 44 cases of past treatment of breast cancer patients 70mg / m ~ 2 intravenous infusion, once every 3 weeks, monotherapy. The trial did not prevent the use of granulocyte colony-stimulating factor. Efficacy and toxicity were evaluated by the World Health Organization (WHO) efficacy and acute and subacute toxicity response standard of anticancer drugs, and card status score was used to evaluate the changes of body conditions. Results Among 41 evaluable patients, 4 achieved complete remission and 14 achieved partial remission with an effective rate of 43.9% and a clinical benefit rate of 85.4%. Adverse reactions mainly manifested as Ⅲ, Ⅳ leukopenia (42.9%), alopecia (7.1%) and gastrointestinal reactions (4.8%). Shuinazhuliu did not appear. Conclusion Docetaxel injection for the treatment of advanced breast cancer patients with advanced chemotherapy has significant curative effect and good tolerability, which can be used as the treatment option for these patients.